Suzhou Enhua Biopharmaceutical

Suzhou Enhua Biopharmaceutical is a specialized research and development subsidiary of Jiangsu Enhua Pharmaceutical, a leading Chinese pharmaceutical company focused on the central nervous system (CNS) market. Based in the Suzhou Industrial Park, the company is dedicated to the discovery and clinical development of innovative small molecule drugs for anesthesia, analgesia, and psychiatric disorders. Its portfolio includes high-profile licensed assets like oliceridine, a G-protein biased mu-opioid receptor agonist, alongside a growing internal pipeline of candidates targeting schizophrenia and depression. Suzhou Enhua plays a pivotal role in the parent company's transition from a generic-focused manufacturer to an innovation-led biopharmaceutical leader. The company maintains state-of-the-art R&D facilities and collaborates with global partners to bring advanced CNS therapies to the Chinese market.